Targeting MET in advanced and metastatic non-small cell lung cancer: a literature review of the current landscape
Amanda Herrmann, Christopher Grant, Lyudmila Bazhenova · 2025
Read Targeting MET in advanced and metastatic non-small cell lung cancer: a literature review of the current landscape by Amanda Herrmann, Christopher Grant, Lyudmila Bazhenova (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12776180.txt.
Description
Amanda Herrmann, Christopher Grant, and Lyudmila Bazhenova review targeted treatment for a lung cancer gene pathway in a 2025 article. Changes in the MET gene can drive non small cell lung cancer on their own or help it resist other drugs. The review covers the last decade of work on this pathway.
Four kinds of MET change are covered: a skipped gene segment, extra gene copies, excess protein, and gene fusions. For each, the authors sum up how it is detected and classified. Treatment options include blocking drugs, antibodies, dual target antibodies, and drug carrying antibodies. Approved options remain limited, and the authors map key challenges and future directions for the field.
Catalog record
| CREATOR | Amanda Herrmann, Christopher Grant, Lyudmila Bazhenova |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 93 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |